Developing a therapeutic elastase that stimulates anti-tumor immunity by selectively killing cancer cells.
1/5 보강
PICO 자동 추출 (휴리스틱, conf 2/4)
유사 논문P · Population 대상 환자/모집단
45 patient samples to develop N17350, a therapeutic elastase that targets the "neutrophil elastase pathway" to induce tumor regression and stimulate anti-tumor immunity.
I · Intervention 중재 / 시술
추출되지 않음
C · Comparison 대조 / 비교
추출되지 않음
O · Outcome 결과 / 결론
N17350 maintains potency with repeated dosing and across diverse treatment histories, including resistance to chemotherapies and checkpoint inhibitors. These findings support the advancement of N17350 to first-in-human clinical trials as a cytotoxic agent designed to stimulate anti-tumor immunity by selectively killing cancer cells.
Recent clinical studies highlight the effectiveness of combining cytotoxic agents with immunotherapies, emphasizing the need for next-generation treatments that integrate both therapeutic approaches.
APA
Gujar R, Cui C, et al. (2025). Developing a therapeutic elastase that stimulates anti-tumor immunity by selectively killing cancer cells.. Cell reports. Medicine, 6(11), 102446. https://doi.org/10.1016/j.xcrm.2025.102446
MLA
Gujar R, et al.. "Developing a therapeutic elastase that stimulates anti-tumor immunity by selectively killing cancer cells.." Cell reports. Medicine, vol. 6, no. 11, 2025, pp. 102446.
PMID
41205593 ↗
Abstract 한글 요약
Recent clinical studies highlight the effectiveness of combining cytotoxic agents with immunotherapies, emphasizing the need for next-generation treatments that integrate both therapeutic approaches. Here, we use 30 cancer cell lines, 15 tumor models, and 45 patient samples to develop N17350, a therapeutic elastase that targets the "neutrophil elastase pathway" to induce tumor regression and stimulate anti-tumor immunity. N17350 leverages linker histone H1.0 and H1.2, proteins elevated in many cancers, to trigger immunogenic cancer cell death while preserving immune cells. Intra-tumoral N17350 administration induces rapid, genotype-independent tumor regression, triggering CD8 T cell activation to promote durable responses and enable checkpoint inhibitor efficacy in refractory models. N17350 maintains potency with repeated dosing and across diverse treatment histories, including resistance to chemotherapies and checkpoint inhibitors. These findings support the advancement of N17350 to first-in-human clinical trials as a cytotoxic agent designed to stimulate anti-tumor immunity by selectively killing cancer cells.
🏷️ 키워드 / MeSH 📖 같은 키워드 OA만
- Humans
- Neoplasms
- Cell Line
- Tumor
- Animals
- CD8-Positive T-Lymphocytes
- Mice
- Leukocyte Elastase
- Immunotherapy
- Histones
- Female
- Immune Checkpoint Inhibitors
- Antineoplastic Agents
- Xenograft Model Antitumor Assays
- ELANE pathway
- N17350
- abscopal effect
- cytotoxic therapeutic
- elastase
- histone H1
- immunogenic cell death
- immunotherapy
- pan-cancer
- selective cancer killing
🏷️ 같은 키워드 · 무료전문 — 이 논문 MeSH/keyword 기반
- A Phase I Study of Hydroxychloroquine and Suba-Itraconazole in Men with Biochemical Relapse of Prostate Cancer (HITMAN-PC): Dose Escalation Results.
- Self-management of male urinary symptoms: qualitative findings from a primary care trial.
- Clinical and Liquid Biomarkers of 20-Year Prostate Cancer Risk in Men Aged 45 to 70 Years.
- Diagnostic accuracy of Ga-PSMA PET/CT versus multiparametric MRI for preoperative pelvic invasion in the patients with prostate cancer.
- Comprehensive analysis of androgen receptor splice variant target gene expression in prostate cancer.
- Clinical Presentation and Outcomes of Patients Undergoing Surgery for Thyroid Cancer.